Our study aimed to discover new targets for the treatment of asthma, and this study identified six druggable genes (IRF1, OXER1, PSMA4, UNC13D, HLA‐DRB1, and CD226) that provide genetic evidence for the development of drugs for asthma; however, additional studies are needed to assess the feasibility of these six identified druggable genes as therapeutic drugs for asthma. The gene discussed is CD226; the disease is asthma.